Japan approves Dupixent for adults with bullous pemphigoid: full analysis

Regeneron and Sanofi said Japan’s Ministry of Health, Labour and Welfare approved Dupixent (dupilumab) for adults with bullous pemphigoid on March 24, 2026, making it the first targeted medicine approved for the condition in Japan. The companies framed the decision as another expansion for a blockbuster immunology brand that has steadily moved from common type 2 inflammatory diseases into rarer dermatology indications. It also lands during a period of broader lifecycle expansion for Regeneron, which recently won an FDA update for Eylea HD allowing dosing intervals up to 20 weeks in wet age-related macular degeneration and diabetic macular edema after one year of response. (sanofi.com)

The approval builds on a sequence of milestones over the past 18 months. In September 2024, Sanofi and Regeneron reported that the pivotal LIBERTY-BP ADEPT phase 2/3 trial met its primary and key secondary endpoints in adults with moderate-to-severe bullous pemphigoid. In February 2025, the companies said the FDA had accepted the supplemental biologics license application for priority review, and in June 2025, the US approved Dupixent for adult patients with bullous pemphigoid. Company filings have also indicated that an EU decision has been pending in 2026. (sanofi.com)

According to Sanofi’s Japan approval announcement, the MHLW decision was based on ADEPT data showing that over four times more dupilumab-treated patients experienced sustained disease remission through Week 36 than patients on placebo. Clinical trial materials and company disclosures describe ADEPT as a randomized, double-blind, placebo-controlled study in 106 adults with bullous pemphigoid. The primary endpoint required complete remission with oral corticosteroids tapered off by Week 16, no relapse, and no rescue therapy through Week 36. In the earlier topline release, 20% of dupilumab-treated patients met that endpoint versus 4% on placebo, alongside improvements in itch and reductions in rescue therapy and steroid exposure. (sanofi.com)

That steroid-sparing angle is central to the commercial and clinical story. Bullous pemphigoid typically affects older adults, and standard treatment often relies heavily on systemic corticosteroids, which can be difficult to manage in a frail population already at risk for infection and other complications. Sanofi has repeatedly emphasized that Dupixent is the first medicine to show a significant steroid-sparing effect in this disease, while dermatology trade coverage around the AAD 2025 data presentation highlighted improvements in disease activity and itch, not just remission. (sanofi.com)

Expert reaction in open sources was limited mostly to company statements and conference coverage, rather than independent commentary tied directly to the Japan decision. In those materials, Sanofi executives described bullous pemphigoid as debilitating and said the data reinforce the role of type 2 inflammation in the disease. Conference reporting from AAD 2025 also characterized the results as clinically meaningful for a population with high morbidity and quality-of-life burden. That’s not the same as broad external consensus, but it does suggest the approval is landing in a field that has had few targeted options. (sanofi.com)

For Regeneron, the Japan Dupixent decision also fits a wider pattern of extracting more value from established biologics through label expansion and convenience gains. In ophthalmology, the FDA recently approved extending Eylea HD dosing intervals up to 20 weeks for wet AMD and DME after one year of response, based on 96-week PULSAR and PHOTON data. Those studies included 583 patients with wet AMD and 395 with DME; 71% and 72%, respectively, reached final assigned dosing intervals of at least 16 weeks, while 47% and 44% reached at least 20 weeks. The FDA has also set an April 2026 action date for a prefilled syringe version of Eylea HD under a CMC prior-approval supplement review. That development is outside dermatology, but it underscores the same strategic theme: mature biologic brands are being pushed into longer-duration, broader-use, or easier-to-administer formats. (PharmaShots)

Why it matters: For veterinary professionals, this is less about immediate prescribing relevance and more about the direction of comparative medicine. Autoimmune blistering disease is uncommon in dogs and cats, and dupilumab is not a veterinary-labeled therapy. Still, the human data matter because they strengthen the case for cytokine-pathway targeting in inflammatory skin disease, especially when steroid minimization is part of the value proposition. In specialty practice, referral dermatologists and internists increasingly track human biologic development as an early indicator of where future animal health innovation may emerge, whether through species-specific monoclonals, repurposing research, or biomarker-led case stratification. The parallel Eylea HD update is a useful reminder that big biopharma value creation often comes not just from new molecules, but from stretching dosing intervals, refining delivery, and broadening approved use — all themes with eventual relevance to veterinary biologics as that market matures. (sanofi.com)

There’s also a business signal here. Dupixent has become a platform product for Sanofi and Regeneron, with approvals in Japan spanning atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, prurigo nodularis, chronic spontaneous urticaria, and COPD, in addition to bullous pemphigoid. That breadth shows how companies are extending a single immunology asset across multiple inflammatory diseases once mechanism, safety, and regulatory familiarity are established. Veterinary drug developers have followed a similar logic on a smaller scale, so these human milestones can offer a preview of which immune targets may attract more translational interest. Regeneron’s contemporaneous Eylea HD label expansion tells a similar lifecycle-management story in another specialty area. (sanofi.com)

What to watch: The next key marker is whether European regulators follow Japan and the US with an approval decision in 2026, whether fuller peer-reviewed publication of ADEPT data sharpens understanding of durability, safety, and patient selection in this older, medically complex population, and whether Regeneron hits its April 2026 FDA action date for the Eylea HD prefilled syringe. (fortune.com)